FDA Clearance Tracker · P150035
Aveir VR Leadless System
Last checked: Nov 19, 2026Latest source record: Mar 31, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Mar 31, 2022
Approved
Time to decision
2,368 days
Received Oct 6, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150035
- Device name
- Aveir VR Leadless System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Oct 6, 2015
- Decided
- Mar 31, 2022
- Decision
- Approved
- Supplements
- 42 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Leadless pacemaker (PNJ)
- Device class
- Class III
- Regulation
- 21 CFR 870.3610
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the Aveir Leadless Pacemaker, Aveir Delivery System Catheter, and Aveir Link Module.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PNJ. The earliest in FDA's data is P150033, decided Apr 6, 2016.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.